Clinical trials: Pulmonary Metastasis
Neoplastic Disease, Solid Tumor
Indocyanine Green (ICG) Guided Tumor Resection
This is a study to assess the ability of Indocyanine Green (ICG) to identify neoplastic disease. For many pediatric solid tumors, complete resection of the primary site and/or metastatic deposits is critical for achieving a cure.
- Trial name
- NCT04084067
- Testing
- Indocyanine Green
- Where
- United States
- Volunteers
- 215 people
- Sponsor
- St. Jude Children's Research Hospital
NSCLC
A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC
The goal of this clinical trial is to compare the efficacy similarities between QL2107 and Keytruda in metastatic non-squamous NSCLC.
- Trial name
- NCT06754644
- Testing
- QL2107, Pemetrexed, Carboplatin
- Where
- China
- Volunteers
- 808 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Lung Cancer
Radiation Therapy in Preventing Brain Metastases in Patients With Small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which regimen of radiation therapy may be more effective in preventing brain metastases.
- Trial name
- NCT00006344
- Testing
- radiation therapy
- Where
- United States
- Sponsor
- Virginia Commonwealth University
Endocrine/Neuroendocrine, Non-Small Cell Lung Cancer
Non-Viral TCR Gene Therapy
Background: A person s white blood cells can be modified in a lab to recognize certain changes in their tumor. Many of these cells are collected from the person, modified, then given back to the person.
- Conditions
- Endocrine/Neuroendocrine, Non-Small Cell Lung Cancer, Breast Cancer, Gastrointestinal/Genitourinary Cancers
- Trial name
- NCT04102436
- Testing
- Fludarabine, Cyclophosphamide, Aldesleukin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer, Radiation Toxicity
Flaxseed Supplement in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Undergoing Chemotherapy and Radiation Therapy
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Flaxseed may help protect normal cells from the side effects of radiation therapy.
- Trial name
- NCT00955942
- Testing
- flaxseed
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Carcinoma, Non-Small-Cell Lung
Study Of Use Of Pemetrexed In Patients With Non-Small Lung Cancer Metastatic In Andalusian Public Health System
STUDY OF USE OF PEMETREXED IN PATIENTS WITH NON-SMALL LUNG CANCER METASTATIC IN ANDALUSIAN PUBLIC HEALTH SYSTEM
- Trial name
- NCT01877902
- Where
- 18 sites in Spain
- Volunteers
- 190 people
- Sponsor
- Fundación Pública Andaluza Progreso y Salud
Melanoma, Lung Cancer
Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC
This is a 2-part prospective trial examining the ability of Stereotactic Body Radiation Therapy (SBRT) to induce a response to MK-3475, a humanized antibody to PD-1, in patients who progress on this antibody.
- Trial name
- NCT02407171
- Testing
- MK-3475, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Yale University
Metastatic Non-Small Cell Lung Cancer
Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
The primary hypothesis is that pembrolizumab/vibostolimab (MK-7684A) in combination with chemotherapy is superior to pembrolizumab in combination with chemotherapy with respect to overall survival (OS) in participants with…
- Trial name
- NCT05226598
- Testing
- Pembrolizumab/Vibostolimab, Carboplatin, Cisplatin
- Where
- 149 sites in United States, Argentina and 17 more
- Volunteers
- 739 people
- Sponsor
- Merck Sharp & Dohme LLC
Non Small Cell Lung Cancer
Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer
To compare the efficacy of pegilodecakin in combination with nivolumab versus nivolumab alone in participants with metastatic non-small cell lung cancer as measured by objective response rate.
- Trial name
- Cypress 2 (NCT03382912)
- Testing
- Pegilodecakin, Nivolumab
- Where
- 35 sites in United States
- Volunteers
- 52 people
- Sponsor
- Eli Lilly and Company
Lung Adenocarcinoma, Lung Cancer
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
The purpose of this study is to determine the safety, tolerability and overall response rate of trametinib when given in combination with erlotinib in patients with Stage IV or recurrent lung adenocarcinoma that cannot be treated…
- Conditions
- Lung Adenocarcinoma, Lung Cancer, Lung Cancer Metastatic, Lung Cancer Stage IV
- Trial name
- NCT03076164
- Testing
- Trametinib, Erlotinib
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-small Cell Lung Cancer
NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC
Phase 2a Open-Label, Multicenter Trial of Naptumomab Estafenatox (NAP), following Obinutuzumab Pretreatment, on Days -13 and -12. NAP will be administered on Days 1-4 of treatment cycles 1-6, followed by docetaxel on Day 5.
- Trial name
- NT-NAP-102-1 (NCT04880863)
- Testing
- NAP (Naptumomab estafenatox), Docetaxel, Obinutuzumab
- Where
- 11 sites in United States
- Volunteers
- 38 people
- Sponsor
- NeoTX Therapeutics Ltd.
Gut Microbiota, NSCLC
Analysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembrolizumab Combined With Chemotherapy
Analysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembrolizumab Combined With Chemotherapy
- Conditions
- Gut Microbiota, NSCLC, Pembrolizumab, Chemotherapy
- Trial name
- NCT04333004
- Testing
- Pembrolizumab Combined With Chemotherapy
- Volunteers
- 40 people
- Sponsor
- Xiaorong Dong
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
RATIONALE: Thalidomide may stop the growth of neuroendocrine tumors by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who have metastatic neuroendocrine…
- Conditions
- Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome
- Trial name
- NCT00027638
- Testing
- thalidomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-small Cell Lung Cancer
Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations
This is a phase II single-arm open label trial to evaluate the intracranial efficacy of capmatinib in advanced stage NSCLC with asymptomatic BM with positive MET amplification or METΔex14 detected on cfDNA.
- Trial name
- NCT05567055
- Testing
- Capmatinib
- Sponsor
- Timothy Burns, MD, PHD
Non Small Cell Lung Cancer
TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)
This is a multi-center, randomized, open-label, Phase III clinical trial which compares the safety and efficacy of TGRX-326 with crizotinib in patients with ALK-positive advanced or metastatic NSCLC
- Trial name
- NCT06082635
- Testing
- TGRX-326, Crizotinib
- Where
- China
- Volunteers
- 321 people
- Sponsor
- Shenzhen TargetRx Co., Ltd.
Metastatic Non Small Cell Lung Cancer
Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations
This is a Phase 4, open label, single arm, multi-center, prospective clinical trial of dacomitinib that will be performed in India.
- Trial name
- NCT04511533
- Testing
- Dacomitinib
- Where
- 15 sites in India
- Volunteers
- 101 people
- Sponsor
- Pfizer
Neoplasms, Lung
The Immunotherapy of Nasopharyngeal Cancer Using Cancer Stem Cells Vaccine
Most studies of cancer stem cells (CSC) involve the inoculation of cells from human tumors into immunosuppressed mice, preventing an assessment on the immunologic interactions and effects of CSCs.
- Trial name
- NCT02115958
- Testing
- cancer stem cell vaccine
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Non-small Cell Lung Cancer Metastatic
Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC
In recent years, immunotherapy research has made great progress, especially the immunocheckpoint inhibitors represented by anti-pd-1 antibody have shown good efficacy in the treatment of malignant tumors, and some patients can…
- Trial name
- NCT04331626
- Testing
- Gemcitabine Injectable Product
- Volunteers
- 50 people
- Sponsor
- Henan Cancer Hospital
Osteosarcoma, Pulmonary Metastasis
Safety and Feasibility of Intraoperative Visualization With Cytalux in Children
Pediatric subjects aged 6-17 with biopsy confirmed cancer and imaging findings suspicious for pulmonary metastatic disease scheduled to undergo pulmonary metastasectomy via and open or minimally invasive approach.
- Conditions
- Osteosarcoma, Pulmonary Metastasis, Fluorescence, Metastatic Sarcoma
- Trial name
- Cytalux (NCT06235125)
- Testing
- Cytalux
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Carcinoma, Non-Small-Cell Lung, Neoplasms
A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy
The study is primarily designed to assess the safety and tolerability of escalating oral doses of Debio 1143 and preliminary anti-tumour activity when combined with the standard dose of avelumab in participants with advanced…
- Trial name
- NCT03270176
- Testing
- Debio 1143, Avelumab
- Where
- 9 sites in Canada, Poland and 1 more
- Volunteers
- 54 people
- Sponsor
- Debiopharm International SA
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.